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Abstract
HIV prevalence  in Soutilern  Africa is the highiest  in the  that miglht  have occurred  in  people  who are vaccinated,
world  and  the impact of HlV/AIDS  In thc  rcgion are  and secondary-the  number of peoplc  that the
devastating at  all  levels  of society,  incLidinig  the  wider  vaccinated  individual  would otherwise  have  caused to
cconomly.  Governmiiient  response  has lagged  behilid  the  become  infected.  Both  of these depend  on assumptions
pace of the epidemic,  but programs  are now  begininilg to  about the efficacy  and duration  of vaccine  protection and
focus  on a broad  range  of interventionis  to combat its  the extent and  nature of sexual risk  behavior  in  the
further spread and  to mitigate  its impact.  population1  groups.  The authors distinguish between the
Desimiond  and Greener  investigate  the  issues around  HIV cases averted  per vaccination  and the  cases averted
the targeting  of an eventual  HIV  vaccine. There  is  at  per  100 recruits  into a  vaccination program.
present no vaccine  against  HIV. Althoughl  several  The cases averted  per  100  recruilts  is used to develop  a
candidates are in  the trial stage,  it is  not likely  that a  priority ranking of the  identified  population  groups for
vaccine  effective  against the sub-type  of the virus  vaccination.  The authlors discuss the  issue of ease of
prevalent  in Southern Africa  will  be available  for  I0-IS  access  to those groups and how the  differential  costs
ycars.  When  it is,  it may be expenisive,  only  partially  would affect the  vaccination strategy.  Thev conclude  that
effective,  and  confer immun1ity  for a  Iilimted  period  only,  an expensive  vaccine  should  be administered  to
Vaccinationi  programs  will  need  to make the  best use  of  commercial sex workers  first,  xwhile  an inexpensive
the  vaccine that is  available and  effective  targeting  wvill  be  vaccinie  Would  be better adminlistered  first to general
essential.  population  groups,  in particular,  schoolchildreni.
The authors identify  potcitial target groups  for  a  Dcsmonid  and  Greener conclude  with a  discussion  of
vaccine,  and  estimiate  how  manay  individuals  would  be in  currenit Icvels of public and  private expenditure on  HIV
need of vaccination.  They  develop a  method  for  prevcntioni and trcatment, and the implications  for an
estimating  how  manay  cases of HIV iifectioni  are  likelv to  assessmenlt of the willingness  to pay for  an eventual  HIV
be avoided  for each  vaccinated  individual.  The  cases  vaccine.
avoided  are of two kinds:  primary-the  individual  case
This paper-a product of l'ublic Services,  Development  Research Group-is  part of the rcseartll  projcct "Thc Economics
of an HIV/AlDS Vaccine In Developing CouLntries:  Potential Impact, Cost-Effectiveness,  and Willingiess to Pay"  sponsored
by the European Commissioni and the World Bank. The project was launched in  responsc to recommenidationis  of tie World
Bank's  AIDS  Vaccine  Task  Force.  Copies  of this  paper  are  available  free  from  the  World  Bank,  1818  H  Street NW,
Washinigtoni,  DC 20433. I'lease contact Hedy Sladovich,  mail stop MC3-3  I1, telephonie 202-473-7698, fax 202-522-1154,
email  address  hsladovic]iC.sxvorldbanik.org.  Policy  Research  Working  P'apers  are  also  posted  on  the  Web  at  littp://
econ.worldbank.org. The authors may be contactcd  at desimionldc I @(  nu.ac.za  or rgrecner Cwbidpa.bw.  February  2003.  (47
pagcs)
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children  291.  Introduction
Although the HIV virus appeared later in Southern Africa than elsewhere
on the continent, Southern Africa now has the highest rates of HIV prevalence in
the world. Approximately one adult in five is HIV positive  (see Figure 1-1),  and
Southern African countries face the prospect of the reversal of hard won progress
in development, resulting in deepening human poverty and social dislocation.
Valuable human resources are being lost, affecting all sectors, public as well as
private. HIV/AIDS will hamper governments'  ability to manage their economies
and to deliver social services.
Figure 1-1.  HIV adult prevalence  rates and selected  development  indicators in Southern Africa
Adult HIV  Population  Adult|  GDP/Capita  Secondary
Country  Prevalence  '000  Population  (PPP$)  Seodr
_____  ____  ___  ____  __  _  ____  ___  000  _  _  _  _  _  Enrolm ent
South Africa  19.9%  43,421  20,630  $8,908  56%
Zimbabwe  25.1%  11,343  5,771  $2,876
Zambia  20.0%  9,582  4,137  $756
Lesotho  23.6%  2,143  998  $1,854  18%
Namibia  19.5%  1,771  790  $5,468  38%
Botswana  35.8%  1,695  775  $6,872  48%
Swaziland  25.3%  1,083  480  $3,987  38%
Overall  Total  21.4%  71,038  33,581  $6,423  53%
Sources.  UNAIDS website  (HIV prevalence),  UNDP  (2001).
1.1.  Approach of the Paper
The principal goal of this paper is to provide a framework for comparing
different AIDS vaccination strategies to guide the process of targeting, should that
become necessary.  The paper begins with a brief review of the health and
developmental impacts of HIV/AIDS in Southern Africa,  and the current
responses in the seven countries considered with regard to prevention,  treatment
and vaccine development.
In section 2, the paper presents an analysis based on calculating the total
number of cases averted per 100 entrants into a vaccination program, under the
assumption that prior screening for existing HIV infection  is impractical  and is not
carried out.  This indicator is then calculated for each of 12 identified risk groups
and used to rank them in order of effectiveness.  This leads to a discussion  of
access and targeting issues.
In section 3, the paper presents evidence of existing ability and willingness
to pay for an HIV vaccine, based upon expenditure on other health items or
vaccines,  and a brief analysis of economic motivation.  The paper concludes with
recommendations for vaccination strategies under differing assumptions about the
cost, efficacy and duration of protection offered by any potential vaccine.
11.2.  The Health and  Development Impacts of  HIV/AIDS in Southern Africa
HIV prevalence
The estimated adult prevalence  of HIV in selected countries of Southern
Africa is shown in Figure  1-1.  South Africa is by far the largest of the countries
listed, with about 61 percent  of the adult population of the region, and therefore
dominates the overall average  rate of 21.4 percent.  There are, however,
considerable regional variations within South Africa, with rates above 30 percent
in KwaZulu Natal, and below 10 percent in the Western  Cape. The highest
regional rate of 35.8 percent is found in Botswana.
The figure also shows the populations (both total and adult - i.e., aged  15-
49), the per-capita GDP and the net secondary school enrollment ratios. All of the
totals shown in the table are weighted by population from the countries where
data were available.
Demographic impact
The demographic impacts of HIV/AIDS arise through its impact on
mortality and fertility. Deaths due to AIDS can be expected to cause a dramatic
increase in the mortality rates in the  15-49 age group, where they would otherwise
be expected to be very low. In the case of infant mortality, there is clear evidence
from Botswana and other African countries that HIV/AIDS has caused a
stagnation or even a rise in infant and child mortality rates (Timaeus  1998).
The demographic impact of HIV/AIDS is often measured in terms of life
expectancy. Life expectancy is, however, an unsatisfactory  indicator, since it
depends upon assumptions about age and sex specific mortality rates. Accurate
measures of age specific mortality are difficult to obtain, and most published
estimates of life expectancy make use of mortality rate projections. These
projections have not yet been validated against national population census data
since such data are usually only collected every  10 years. Both South Africa and
Botswana have recently conducted population censuses, and results from these
will in due course yield estimates of mortality. Early estimates from the Botswana
census (no official publication is yet available)  indicate that the projections  used to
date in life expectancy  calculations are not valid.
The evidence from survey data gives some indication of impact. Figure 1-2
below shows measures of adult mortality by age and sex from Botswana (1997
demographic survey)  as compared with mortality (in dotted lines) as measured in
the 1991 population census. There is clear evidence of substantially raised
mortality in the 25 to 40 age groups.
2Figure 1-2.  Adult mortality in Botswana  by age  and gender, 1991  and 1997/98
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As indicated above, however, these raised mortality rates are substantially
below the rates that had been projected for the year  1997/98 - for example, see
Botswana MFDP (2000a). In addition,  early estimates for the total head count from
the Botswana population census in 2001 indicate a total of almost 1.7 million. This
is close to projections obtained  before HIV/AIDS was accounted for, and is at the
very high end of AIDS scenario projections produced prior to the census  (most of
these were in the range  1.4-1.6 million). In the case of Botswana, it may be that the
period from infection to death is higher than was previously expected, but this
may not apply across all of the Southern African countries.
A recent study by the Medical Research Council  (MRC) in South Africa
(MRC 2000) documented the steady rise in adult mortality during the 1990's, with
female mortality in the 25-29 age group increasing by a factor of 3.5 between 1985
and 2001.  AIDS deaths were broadly compatible with a number of different
projection models, in particular the ASSA600 model produced by the Actuarial
Society of South Africa (ASSA). The report concluded:
While there is inevitably some degree of uncertainty because of the assumptions underlying both
the model and the interpretation of the empirical data, we estimate that about  40 percent of the
adult deaths aged 15-49 that occurred in the year 2000 were due to HIV/AIDS and that abuut  20
percent of all adult deaths in that year were due to AIDS. When  this is combined  with the excess
deaths in childhood, it is estimated that AIDS accounted for about 25 percent of all deaths in the
year 2000 and has become the single biggest cause of death. The projections show that, without
treatment to prevent AIDS, the number of AIDS deaths can be expected to grow. within the next
10 years, to more than double the number of deaths due to all other causes, resulting in 5 to 7
million cumulative AIDS deaths in South Africa by 2010.
3Economic  impact
The expected economic impacts of HIV/AIDS arise through several
identified mechanisms. First, the increased mortality among young adults depletes
the most economically productive part of the population, reducing the supply of
labour across all skill categories.  In addition, raised mortality among older, more
experienced workers will tend to reduce the average level of work experience
among the workforce. The resulting loss of skills will cause a reduction in
productivity.
Second, there is an increase in morbidity among workers who are
beginning to suffer the symptoms of AIDS. This will have the effect of reducing
the average level of productivity,  and hence the aggregate level of output.
Third, households will face reduced incomes because of the loss of income
earners, at the same time facing higher expenditures because of additional
demands for health care. This will have the effect of increasing the levels of
poverty and reducing the levels of savings in the economy. The capital available
for investment will therefore be reduced, with a negative impact on aggregate
economic growth. For example,  Greener, Jefferis, and Siphambe  (2000a)  found that
income poverty over a 10-year period might be expected to increase by at least 5
percentage points over what it otherwise might have been.
At a government level, there will tend to be a reduction in revenue from
taxation and other sources as a result of reduced  economic growth. At the same
time, there will be pressure to increase expenditures  on health care and welfare to
mitigate the impacts of HIV/AIDS. This will have the effect of pushing
governments towards the need for deficit spending or reducing expenditure  on
other development areas. In particular,  the costs of AIDS treatment will, in the
first instance, be borne by governments. For example, Greener,  Jefferis, and
Siphambe  (2000a) found that the net impact on the government budget over a 10-
year period in Botswana would be equivalent  to a 20percent reduction in revenue.
Pressure on health budgets may also cause a "crowding out" effect, where.
expenditure on other health priorities may decrease. This effect may cause further
economic impacts not directly related to HIV/AIDS.
AIDS will also cause human resource problems for firms and organisations,
which may lose employees in vital skill areas and face difficulty in recruitment
and training.
Numerous studies over the last 10 years have found estimates of the
probable size of aggregate macroeconomic  impact, mainly in African countries
where the epidemic is the most serious. Results have indicated that HIV/AIDS
will probably reduce the growth rate of Gross Domestic Product  (GDP) by
between 0.5 percent and 2.6 percent. For example, see Over (1992),  Kambou,
Devarajan, and Over (1992),  Cuddington  (1993a, b), Bloom and Mahal  (1995),
Arndt and Lewis (2000), Greener, Jefferis and Siphambe (2000a,b)  and Bureau  for
Economic Research  (2001). The overall conclusion of these studies is that the
aggregate impact of HIV/AIDS on GDP growth is quite small and well within the
4range of variation that would be caused through the normal instruments of
economic management.
Development  impacts
The HIV/AIDS epidemic is placing a severe burden on all levels of the
health care system throughout the region.  Hospital admissions are increasing
rapidly and more than half of the available hospital beds are occupied by AIDS
related cases, including tuberculosis.  For example see Botswana MFDP  (2000b).
The epidemic is threatening to overwhelm the health services, and the expansion
of home based care facilities for AIDS patients is inevitable.
The HIV epidemic has fueled a parallel epidemic of tuberculosis  (TB),
exacerbating the problems of the relatively low coverage  of effective TB
immunisation in much of the region. For example,  see Botswana MFDP  (2000a),
and the data presented in Figure 3-1.
The education sector has been severely affected by the HIV/AIDS
epidemic. The death rates among teachers and lecturers have been increasing
sharply in recent years, for example see Botswana MOE and DFID (2000).
Although death rates are low among school students, HIV/AIDS has disrupted
their home environments  as adults fall ill and need to be cared for. There is
speculation about how this situation is affecting  the quality of teaching and the
quality of school work. It is clear that the demographic  impacts of HIV/AIDS will
create significant  planning problems for education in the future.
The rapid spread of HIV/AIDS is exacerbated by a cultural environment in
which issues of sexuality and sexually transmitted  disease are not openly
discussed.  There are a number of pervasive culturally based myths about
HIV/AIDS which reduce the impact of some of the prevention campaigns and
encourage a fatalistic attitude. The issues raised by the epidemic impinge upon
long standing taboos and result in a high level of stigma being associated with
HIV/AIDS, for example see UNDP (2000).
Despite an apparently high level of knowledge about the nature of
HIV/AIDS and how it can be prevented, the steadily rising HIV prevalence  (as
measured in ante-natal clinics) indicates little evidence of a widespread change in
sexual behavior in the region. There is clearly a need to understand the reasons for
this and to understand the possible effects that the introduction of an HIV vaccine
might have.
1.3.  Current responses
The early response to the HIV/AIDS epidemic in Southern Africa, as
elsewher 1e, was essentially biomedical in nature, focusing on increasing national
public awareness  of HIV, training health workers in AIDS clinical management,
and on establishing monitoring systems in ante-natal clinics. This broadened into
efforts to prevent the spread of HIV through media campaigns promoting the use
of condoms or abstaining from sexual activity. The epidemic progressed unabated
however.
5Prevention campaigns  in most countries have emphasized the message of
ABC  (Abstain, Be faithful, Condomize). Some assessments  (for example UNDP
Botswana,  2000)  have concluded that the prevention campaigns have not, to date,
been able to address the true underlying factors that fuel the campaign. These
include intergenerational  sex, poverty and the low status of women.
In recent years, most of the countries considered here have adopted a much
more wide ranging multi-sectoral  approach to HIV/AIDS which seeks to involve
both government and civil society on a broad front. This includes an expansion of
community home based care, and an expansion of life skills training, and a phased
introduction of a range of treatment options. The number of Voluntary
Counselling and Testing (VCT)  Centers  is increasing rapidly. Botswana has begun
to implement a program which ultimately seeks to make AIDS treatment available
to a broad sector of the population.  This program is at an early stage and is not yet
administering ARV treatment to very many people,  but it is clear that the logistics
associated  with widespread ARV treatment will be formidable.  The recent policy
shift in South Africa is likely to lead to a rapid expansion of ARV and other forms
of treatment, particularly for vulnerable  groups such as pregnant or breastfeeding
women.
1.4.  HIVvaccine development
A number of candidate vaccines are currently in or about to begin trials.
This is a result of advances in animal models and clinical research  Johnston and
Flores 2001). A number of vaccine candidates are ready for, or already
undergoing, phase one trials in Europe, the United States and Africa.  Not all HIV
types are the same, and a number of different subtypes exist. These different
subtypes of HIV are prevalent in different parts of the world, but candidate
vaccines are often targeted at one subtype. Therefore,  a vaccine may become
available for some subtypes before others and thus may be used far earlier in some
parts of the world. Subtype A is most prevalent in South Africa.
The current candidates are primarily aimed at subtype B, although at least
one subtype A candidate has begun trials. The most advanced trials are for the
phase three VaxGen candidate  aimed at subtypes B and E.  These  are currently
underway in the United States and Thailand, and interim results are expected  by
the end of this year Uohnston and Flores 2001).  The company responsible  is
already planning for large scale commercial production. This, however, offers
little hope to those fighting the epidemic in Africa, since the B and E subtypes are
not prevalent in the African epidemic.
In South Africa, where subtype A is dominant, phase one trials are set to
begin only this year. Researchers in South Africa believe that a commercially
available vaccine for use in the region is 15 to 20 years away, although there
appears to be consensus that a viable vaccine can be developed  (Morris,
Williamson, and Vardas 2001). The South African government strongly supports
the vaccine initiative and provides funds from the national budget towards its
development and testing, run primarily by the South African Medical Research
6Council. The development of an acceptable  vaccine for use within in South Africa,
and indeed within the continent,  is far less advanced than elsewhere in the world.
2.  Vaccination  strategies
2.1.  Introduction
An ideal HIV vaccine would be cheap, freely available,  a single dose,
simple to administer, one hundred percent effective,  and last a lifetime with no
side effects. Although one day such a vaccine may become available, the first
available vaccines are unlikely to be as ideal. They are more likely to be expensive,
multi-dose, less than 100 percent effective and last only a few years. The
prohibitively high cost may make the widespread provision of early vaccines
unaffordable in many low and middle-income  countries, including those in
Southern Africa.
In such a situation, interventions  will have to make best use of the available
finances and apply the most cost effective and politically acceptable  strategy. This
would involve, amongst other things, the estimation of the effectiveness  of
targeting different groups within the population and the cost of targeting.  The
vaccination  of members of high-risk groups would likely provide the most
effective outcome per vaccine given, but the cost of accessing such groups as
opposed to lower risk groups may be sufficient to make easily accessed, but low
risk, groups a more cost effective target. The political consequences of targeting
high risk groups may also be a major factor influencing target choice.
This section aims to evaluate the conflict between cost and effectiveness
and identify the most cost-effective options for a vaccination strategy, with the
primary focus on where to begin. While it is not possible to make definitive
conclusions while the characteristics  and cost of the possible vaccines are
unknown, it is possible to raise and discuss a number of issues which will expedite
the development of a strategy once the required information has become available.
The section begins with an outline of the method used in the analysis,
which is followed by the results and a discussion of their implications.  As stated
previously, the analysis and discussion concentrates on a vaccine designed to
prevent HIV infection rather than one designed to prevent the progression from
HIV to AIDS.
2.2.  Analysis
The analysis required the estimation of the number of infections averted
when vaccinating  people with different characteristics,  and the relative difficulty
of access to the different groups. This section outlines, in brief, the methods used
in estimating these parameters, while a more detailed explanation is provided in
the appendix.
First, the paper outlines the manner in which the number of infections
averted was calculated, broken into two categories:
7*  The calculation of primary infections averted - i.e., the number of
vaccinated individuals who would otherwise have become infected with
HIV
*  The calculation of secondary  infections averted - i.e., the number of people
who would have become infected by those vaccinated  individuals who
became HIV positive
These calculations together yield an estimate of the total number of
infections averted for vaccinations of HIV negative individuals for the different
groups  (i.e., primary plus secondary).
It was felt, however, that ending the analysis at this point could be
misleading. Estimating the total number of infections averted  masks the problem
(and associated cost) of screening for existing HIV infection,  particularly  among
high-risk candidates.  For this reason, the number of infections averted per one
hundred entrants from a target group was estimated.  The method used for this
calculation is outlined below.
This section outlines the approach taken to deal with the question of
differential access and associated cost. The paper also discusses the method
applied in the selection of possible target groups.
The analysis presented in this paper is a simple and easily understandable
approach, which is aimed at raising important considerations,  rather than at
providing accurate numbers. While it is possible to refine the method to improve
the estimations, this would dramatically increase the computational  complexity,
adding little to the discussions outlined. 1 Due to its simplicity, the approach does
suffer a number of limitations which are outlined in the appendix. Where they
relate to the discussions, they are mentioned in the text.
Method to compare strategies
Primary  infections averted.  The probability of a "primary"  infection refers to
whether or not an individual would have been infected with HIV if they had not
been vaccinated. It does not include the probability that the individual would
have gone on to infect other people. This is referred to as "secondary"  infection,
and is described in the next section.
The number of primary infections averted for a group of HIV negative
vaccinated  individuals will depend on four factors:
*  The efficacy of the vaccine - i.e., the probability that a vaccinated person is
protected from infection
*  The number of people in the group being vaccinated
*  The duration of the period of immunity offered by the vaccine
' For a detailed modeling exercise see Stover and others (2002).
8*  The average probability  that a typical group member would otherwise have
become infected during the period of protection of the vaccine,  called the
"period infection probability."
The meaning of the "period infection probability"  depends on the length of
the period.  If the period under consideration  is one year, then the period
probability is equal to the probability that an individual will be infected during
that year. This is also the definition of the incidence of HIV infection for the group.
For periods of longer than one year, the period probability will depend on the way
in which HIV incidence evolves for the cohort over the period. The evolution of
HIV incidence is in turn dependent upon the expected risk behavior within the
cohort and will vary considerably among different risk groups.
There is, however,  a relationship  between the period probability and the
HIV prevalence in a cohort. In general, a cohort is likely to experience  a high
period probability at the early stages of the onset of risk behavior when prevalence
is low. As the cohort evolves, the period probability will fall as the prevalence
rises, since there are fewer individuals in the cohort left to infect.
The analysis estimated the primary cases averted by simulating the
evolution of prevalence and infection probability for different risk groups. This
made use of the illustrative risk groups as represented  in the simulation  model
developed by the Actuarial Society of South Africa (ASSA).2 Although it is no
substitute for the use of real data (which are lacking),  the benefit of this method  is
that it gives a realistic estimate of the period probability in a Southern African
setting, while arriving at a "best guess"  at the differences  in likely risk behavior
among the different risk groups.
Secondary infections averted. Vaccinating an individual will not only prevent
the infection of that individual, but also the secondary infections that would have
resulted from that individual infecting others. The number of secondary infections
averted will depend upon a variety of factors and will differ substantially for
different individuals.  For example, preventing the infection of a commercial sex
worker will avoid substantially  more secondary infections than preventing the
primary infection of an older woman in a monogamous relationship. Although
there are a host of other factors which must be considered  in designing  a
vaccination program, the number of secondary infections averted is clearly an
important component.
A variety of variables is instrumental in determining the number of
secondary infections averted. These include:
*  the number of sexual partners the individual will have over the period  for
which the vaccine offers protection
*  the number of sexual contacts they have with these partners
2 For details of the ASSA 600 model used in  this analysis, see
www.assa.ora.za/aidsmodel.asp.
9*  their probability of being infected, per sexual contact
*  whether they, or their partners, have a sexually transmitted infection (STI)
*  whether their partners are already infected with HIV
*  the frequency of condom use.
It is necessary to calculate the probable number of people the individual
would have infected if he or she had not been successfully vaccinated. The more
sexual partners and more sexual contacts they have, the higher the number of
people they would infect. Similarly, the greater the individual's probability of
having an STI and the higher the STI prevalence  of their partners, the higher the
probability - per sexual contact - that they would transmit HIV. On the other
hand, the higher their condom use, the lower the probability of transmission per
contact. Finally, the higher the existing level of HIV among their partners, the
lower the chance that their future partners are HIV negative to begin with.
Preventing a repeat infection of an already infected individual is not an infection
averted. When estimating these variables,  it is necessary to consider how
behaviors may differ between casual sexual contacts and long-term partners.
These variables,  as well as those relating to the duration and effectiveness
of vaccines,  interact with one another to determine the number of secondary
infections averted. The implications of these interactions were estimated with a set
of equations, which are outlined in the appendix.
It is also possible that a vaccine may lead to changes in sexual behavior
resulting from changed perceptions of risk. In the calculations presented in this
paper, no attempt has been made to introduce behavior change. The behavior
variables used in the calculations  are based on the data that are available, which
are weak and incomplete. There is, therefore, no quantitative basis for estimating
the impact of a vaccine on behavior change in the different risk groups, so it was
not included in the calculations. However, possible behavior changes will be very
important in vaccination program design, and the implications of changes in
behavior prompted by the introduction  of a vaccine are discussed below.
Total infections averted.  The previous two sections have outlined the basis
for the calculation of the number of primary and secondary infections averted. The
estimation of the total number of infections averted per vaccinated HIV negative
individuals involves the combination of the previous two calculations.
The efficacy of the va,ccine will make no difference to the ranking of
strategies in terms of their effectiveness,  unless vaccination changes risk behavior
differently in different target groups. Given the decision to vaccinate, which
would in part be motivated by the efficacy, the most effective strategies will be the
most effective regardless of the efficacy of the vaccine.  A change in the efficacy
changes the impact of vaccination of all groups by the same proportion and will
not affect their effectiveness  in relation to one another. Changes in the duration of
protection are, however, more important at this stage.
10Changes in the duration  change the probability of averting a primary
infection. This change will have different implications for the effectiveness  of
vaccinations  in different risk groups. Further the sexual behaviors of different
groups will likely vary over time, and a different duration could possibly change
the ranking of groups in terms of both effectiveness and cost effectiveness.  This
issue is discussed in greater detail after the presentation of the results below.
Infections averted per 100 entrants into the program. The method described
above estimates the number of infections averted per vaccine administered to an
HIV negative individual. The vaccination  of an HIV positive individual will result
in no infections averted and may well lead to a false sense of security which could
increase the risk of others. Considering only the number of infections averted in
this way ignores the costs and complications associated with ensuring that only
HIV negative individuals receive vaccinations.  A more meaningful measure
would be the number of infections averted per 100 entrants into a vaccination
program. The basis for this calculation is outlined in the appendix.
The vaccination of members of high-risk groups is likely to avert more
infections than the vaccination of members of lower risk groups. The impact is,
however,  likely to be diluted by the need  to exclude many vaccination candidates
because they are already HIV positive. If the cost of screening is significant,
relative to the cost of a vaccine, this may have important implications for policy.
Policy decisions may be further complicated by the difficulties associated with
locating members of high-risk groups.
Issues of access.  The delivery of an HIV vaccine is likely to differ
substantially from that associated with currently available vaccines. The majority
of currently provided vaccines are administered to young children. The targeting
of different population groups will, in some cases, necessitate the active seeking
out of participants. The difficulty of access and associated cost are likely to be
substantial.
The identified risk groups are classified in terms of their difficulty of access,
rated as easy, medium, difficult or very difficult. These classifications  are made in
terms of once off access and follow up access.  The difficulty associated with
accessing some groups once off may be very different from the difficulty
associated with finding those same people a second or third time for follow up
doses. For example, the recruitment of vaccination candidates at a hospital may be
very easy for once off doses, but locating those same people for repeat doses
would be very difficult.
We do not attempt to quantify the difference in difficulty of access. What is
estimated is how large a difference in cost, associated with different levels of
difficulty, would change the ranking of different strategies.If a program aimed at school girls was targeted at fifteen year olds who
have very low prevalence,3 and the vaccination was offered to all entrants, the
difference in the costs of access and screening when compared to sex workers
would be large. Given the results presented  in Figure 2-1,  if the additional costs
associated with the targeting of sex workers as opposed to school girls was more
than 1.2 times the cost of a vaccinating school girls (including the cost of the dose),
then the vaccination of school girls would be more cost effective per  100 entrant.
Therefore,  particularly if a vaccine requires more than one dose,  a vaccination
intervention may achieve better results by targeting broader population  groups
than difficult to access high risk groups.
Figure 2-1.  Estimated  size of risk groups,  and cases averted
Size  Per  HIV-  Per 100  Access - Access - Group  Catch U  Maintain  HIV+  Pnmary  Secondary  entrant  entrants  once  follow up
Sex Workers  700,000  140,000  66%  0-51  7.88  4.53  154  DiVffcyu  DVffierylt
High SchooI going  2,700,000  94,500  10%  0.34  1.05  0.70  70  Easy  Easy
Military  172,000  10,300  21%  0.25  1.70  068  54  Easy  Easy
Prisoners  214,000  10,700  20%  0.25  1.70  0.68  54  Easy  Easy
High School going  2,600,000  91,000  1%  0.19  1.68  0.51  51  Easy  Easy
Foffai sector  male  8,181,000  490,860  20%  0.25  1.51  0.63  50  Medium  Medium
emDlovees  ..  ._
High schrol  189,000  11,000  26%  030  1 23  0.67  49  Easy  Easy
High risk transport  2,223,000  133,380  56%  0.34  2.17  1.08  47  Difficult  Difficult
workers  ____
Women  attending  1,950,000  117,000  26%  0.33  0.86  0.61  45  Medium  Difficult
ANC
Formal  sector  5,612,000  336,720  26%  0.33  0.80  0.59  45  Medium  Medium
femnalle  employees  I__  __  __I_  _  _  __  _I__  _
Legal cross border  190,000  11,400  42%  0.20  2 39  0.68  44  Difficult  Difficult
m igrm  nts  I__  _  _  _  _  _  _  I__  _  I__I_I_I
Male STD  clinic  42,000  60%  0.30  1.38  0.71  29  Medium  Very
attendoes-  i  I  I ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Difficult
Identification of target  groups. The above calculations and analysis were
performed for twelve different possible target groups. The groups are not
mutually exclusive and are not intended  as a definitive list, but rather as an array
of options to highlight a number of different issues. The groups represent a range
across three characteristics:  risk behavior, ease of access, and size. Sex workers,
high risk transport workers and male STD clinic attendees were selected as the
examples of the high risk behavior, while women attending antenatal clinics and
high school boys represented low risk behavior. Migrants and sex workers
provided examples of difficult to access groups, as opposed to school children
whose ease of access depends upon secondary school enrollment (see Figure 1-1).
3  The prevalence  of all high school girls is assumed to be  10%, the calculations are however
carried  out based on 1% prevalence assuming that only 15 year olds are recruited into the program.
12difficult. A study in Kenya found that there was difficulty  in understanding the
concept of reduced risk (Forsythe 2000).
Second, by the time a vaccine becomes available (in fifteen or twenty years
or even in five), the number of deaths which will have already occurred will be
great. The public response to providing a vaccine only to selected individuals may
be hostile. People will be afraid and possibly become angry at their exclusion,
particularly if it is in favour of sex workers or other high risk groups who they
may perceive to be less worthy of protection than themselves.
Third, many of the possible target groups are women, and this may fuel the
perception that they are responsible for the epidemic.  In the context of high death
rates, this may have potentially damaging implications.
Finally, in many instances  it will not be politically feasible to separate
groups for targeting as they have been in the analysis. The calculation of infections
averted separated schoolboys and girls; while this is useful for discussion
purposes, such a policy in reality would be inequitable and difficult to defend. The
implication would be that school aged children would be the target, rather than
girls.
These few problems highlight that effectiveness  and cost effectiveness  are
only inputs into a decision process, and that the final design of a vaccination
program will have to consider many other economic, social and political aspects.
Indeed, logistics of targeting may be such that the approach will not be
considered.
Some similar problems have occurred in vaccination programs for other
illnesses and efforts should be made to learn from these experiences  (Nichter
1995).
Country-specific  issues relating  to risk group targeting. The analysis thus far
has dealt with the region as a whole and has not discussed specific issues in
relation to each country. While there are many similarities across the region, some
problems may be country specific.
We have argued above in favour of providing a vaccine to high-school
children. Enrollment rates in the region are, however, very different  (see Figure 1-
1). While they are high in South Africa and Botswana, they are very low in
Lesotho. The strength of the cost-effectiveness  analysis is, however, that it allows
for the ranking of interventions.  The most cost effective strategy will always be to
begin with the highest ranking group and vaccinate until the budget runs out or
all of the groups are vaccinated. Low school enrollment alone would not,
therefore, change the recommendations  of the analysis.
Country specific issues may make a difference  if they change the ranking of
groups in terms of their cost effectiveness.  If, for example, high-risk groups are
easier to access in some countries and the cost of access is low, this would make
them a more cost effective option, possibly changing the order of ranking.
21In the case of countries in the region with very high numbers of cross-
border migrants, such as Swaziland and Lesotho, they may represent a high risk
easy access group. It may be possible to set up vaccination sites on the borders and
record in passports the number of doses received. Therefore, while cross border
migrants may not be the most cost effective target group in the region as a whole,
they may be for specific countries. Similarly, sex workers may be easier or harder
to locate in different countries. If sex workers are concentrated in easily identified
urban areas or areas associated with particular industries or activities, then the
costs of access would be lower than an in agricultural setting where they would be
more widely dispersed.
The costs of delivery to all groups may also vary across countries,
particularly in relation to urbanisation, population density and the cost of labour.
Even if these costs vary by the same proportion for each group, it may still change
the differences in cost effectiveness between groups. The importance of delivery
costs is a more important component of total costs for the higher risk groups. A
decrease in delivery costs of equal proportion  across all groups would increase the
cost effectiveness  of high risk groups compared to other groups. This may even
vary the rankings across countries in relation to their costs of labour and transport.
Countries with higher labour costs, such as Botswana, would have added
incentive to target easy to access  groups.
While at this stage when the costs and effectiveness  of a vaccine are
unknown, it is reasonable  to address questions as a region. Once details are
available,  country-specific  assessments and planning will be necessary  to identify
the most cost effective strategies.
3.  Ability and willingness  to pay
3.1.  Trend in the provision of other vaccines
Governments in the region have displayed a mixed attitude towards the provision
of other vaccines. While all of the countries included in the study have vaccination
programs,  primarily aimed at young children, they have succeeded  in reaching
very different levels of coverage.  In Figure  3-1, the coverage rates of the BCG
vaccine against tuberculosis in all the countries  is displayed between  1990 and
2000. Lesotho currently has the lowest coverage with 64 percent, while Zambia is
close to achieving universal coverage. The coverage rates do not appear to reflect
differences in income, as Zambia has achieved some of the highest coverage  rates
but is the poorest country.
22Figure 3-1.  BCG vaccination  coverage  in selected  Southern African Countries
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Not only does the figure display the very different levels of coverage, but
also different trends. Coverage in Lesotho was declining until  1996, while now it is
apparently on the increase,  although the rise is very slow.  South Africa, on the
other hand, has been increasing its coverage, with a very dramatic rise since the
1994 elections.
What can be surmised from the above is that governments in the region are
willing to use vaccination programs as a major health intervention, but that their
commitment towards them is uneven.  Zambia and South Africa,  and Botswana to
some extent have shown very positive attitudes towards childhood vaccines with
either high or rapidly increasing levels of coverage.
3.2.  Current  spending
Estimating the level of government expenditure on HIV/AIDS is difficult,
as much of it is too intertwined with other expenditures to be separated. For
example, spending on medical care for AIDS patients is difficult to distinguish
from other health care spending. It is easier to estimate the level of spending on
HIV programs. This spending provides an indication of the level of government
commitment to fighting HIV directly. When an HIV vaccine becomes available,
government will probably draw on these types of directly allocated funds.
Unfortunately comparable data are not available  for all the countries in the
region. Figure 3-2 provides estimated levels of government expenditure on HIV
related programs. It also shows the level of international donor support and what
these funding levels mean in terms of funds per HIV positive person.
23Figure 3-2.  Reported HIV/AIDS  funding at current prices and exchange  rates (US$),  selected  South
African countriesl996
National  International  Funds per HIV+  Funds per HIV+
Countty  Govemment  Donors  person (total)  person  (national)
Botswana  2,711,640  - 14.27  14.27
Namibia  435,700  764,000  8.00  2.90
Zambia  190,878  6,023,688  8.07  0.25
Zimbabwe  43,802  13,933,725  9.23  0.03
Source UNAIDS  (1999).
In South Africa, the national government allocations are somewhat larger.
In the most recent budget, one billion Rand is allocated to HIV programs (Hickey
2002).  This figure is roughly the same as Botswana in terms of funds per HIV
positive individual,  although South Africa does receive additional donor support.
Included in the funds allocated to HIV in South Africa is the government's
support for the AIDS Vaccine Initiative, which displays a commitment to the
development and use of a vaccine.
Recently, the above pattern has changed  somewhat, Botswana has begun to
receive large amounts of international support, and some countries in the region
are gaining access to monies from the Global fund. While the figures here may be
a little outdated, what is clearly displayed is the variation in the ability and
willingness of governments in the region to support HIV programs. This variation
is also likely to exist in countries' ability and willingness to pay for vaccine
provision. The extent to which these variations will occur is likely to be
determined by the constraints on supply. If a vaccine is expensive and there is no
international support for purchasing, those countries with more serious budgetary
limitations will be more constrained in the development of their programs.
As mentioned previously, the spending outlined above does not include
amounts associated with increases in medical care costs or intertwined in other
expenditures of government. The middle income countries in the region with
better equipped health services, for example, will have greater motivation to
vaccinate to avoid costs associated  with increased demand.
The low levels of funding and the high level of reliance on international
donors are clearly apparent. With the exception of Botswana and South Africa
(and possibly Namibia), the large-scale provision of a vaccine with any significant
cost would clearly be unattainable with the current expenditure  allocation and
without the support of the international community. Targeting strategies would
have to be used in the context of highly restricted budgets, more so in the low-
income countries in the region,  unless substantial vaccine purchase support is
provided.
3.3.  Economic motivation and willingness to pay
Should a vaccine become available, many individuals may be willing to pay
for themselves to be vaccinated.  HIV in the region is, however, largely perceived
24Appendix 1.  Data and Assumptions
The assumptions about population-sizes,  HIV prevalence, HIV incidence and sexual behavior are all contained in the table shown in
Figure 1.
Figure  1. Table of Assumptions
South Africa  Namibla  Botswana  Lesotho  Swaziland  Zimbabwe  Zambia  Total  Assumptions
Total  Population '000  43,421  1,771  1,695  2,143  1,083  11,343  9,582  71,038  SADC website www.sadc.int
Population
Sex  Population '000  434  18  17  21  11  113  96  710  1%  of population
Workers  HIV prevalence  61%  86%  69%  66%  SA prevalence the average of
___________  ~~~~~available  studies
Partner HIV prevalence  38%  38%  SA: average adult population
_______________________  ____________  __________  ________  ~~~~~~~~~~~and  high risk clients
5 yr Period probability  50%  14%  28%  40%  ASSA simulation, female
STI prevalence  19%  19%  Country fact sheets
Partner STi prevalence  12%  14%  12%  DHS South Africa
#  regular partners  1  1  1  SA split as Zambia
# regular contacts  600  720  622
Regular condom use  44%  44%  Adetunji and others (2000,
#  new contacts  3,240  1,560  2,936  2  contacts per client
new condom use  54%  54%  Adetunji  and others (2000,
Males  Population '000  434  18  17  21  11  113  96  710  1%  of population
attending  HIV prevalence  42%  54%  54%  50%  65%  60%  average of available clinic
STD Clinics  data
Partner HIV prevalence  56%  64%  86%  69%  63%  sex worker prevalence
5 yr Period probability  41%  35%  35%  37%  29%  26%  30%  ASSA simulation,  male PRO
__________  ~~~~~~~group
STi prevalence  100%  100%  100%  100%  100%  100%  100%  100%  by definition
Partner STi  prevalence  12%  14%  12%  DHS South Africa
#  regular partners  1  1
# regular contacts  600  600
Regular condom  use  6%  6%  DHS South Africa
#  new contacts  300  300
new condom use  26%  26%  Adetunji and others (2000.
___________  ~~~~~~~~~2001)
Military  Population  '000  85  12  9  2  3  39  22  172  The Stockholm International
Peace Research  Institute
._________  _  _(SIRPRI):www.first_sipn  org
33South Africa  Namibia  Botswana  Lesotho  Swaziland  Zimbabwe  Zambia  Total  Assumptions
HIV prevalence  20%  28%  21%  SA study, Botswana ASSA
simulation
Partner  HIV prevalence  25%  35%  26%  SA study, Botswana ASSA
_ _ _ _ _ _ __  _  _simulation
5 yr Period probability  25%  24%  25%  ASSA simulation, male RSK
STI_______________________  prevalence___  12%______  14%______  12%________  DHS______  group
STI  prevalence  12%  14%  12%  DHS South Africa
Partner STI  prevalence  12%  14%  12%  DHS South Africa
# regular partners  1  1
#  regular contacts  600  600
Regular  condom use  6%  19%  9%  Adetunji and others (2000.
2001), DHS South Africa
#  new  contacts  300  300
new  condom  use  50%  29%  42%  AdetunJi and others (2000,
2001)
Prisoners  Population  000  163  4  6  3  2  19  16  214  website
HIV  prevalence  20%  28%  20%  SA study, Botswana ASSA
simulation
Partner HIV prevalence  20%  23%  20%  SA study, Botswana  ASSA
simulation
5 yr Period  probability  25%  24%  25%  ASSA simulation, male RSK
STI_ prevalence  12%_  14%  12%  DHSSgroup
STI prevalence  12%  14%  12%  DHS South Africa
Partner STI  prevalence  12%  14%  12%  DHS South Africa
# regular partners  1  1
#  regular contacts  600  600
Regular condom use  6%  19%  7%  Adetunji and others (2000,
2001). DHS South Africa
# new contacts  300  300
new condom  use  50%  29%  40%  Adetunji and others  (2000,
2001)
Male  Population'000  5,167  204  148  120  17  1,850  676  8,181  gender split in Zimbabwe
Formnal  and Zambia, and Eomploe  employment in  Namibia Ernployed  based on averages  from other
countries
HIV prevalence  20%  28%  20%  SA study, Botswana  ASSA
simulation
Partner  HIV prevalence  25%  22%  39%  27%  34%  27%  25%  ANC prevalence
5 yr Period probability  25%  24%  25%  ASSA simulation, male RSK
group
STI  prevalence  12%  14%  12%  DHS South Africa
Partner STI  prevalence  12%  14%  12%  DHS  South Africa
34South Africa  Namibia  Botswana  Lesotho  Swaziland  Zimbabwe  Zambia  Total  Assumptions
# regular partners  1  1
#  regular contacts  600  600
Regular condom use  6%  19%  8%  AdetunJi and others (2000,
2001), DHS South Africa
#new  contacts  300  300
new condom use  50%  29%  44%  Adetunji and others (2000,
______________________________  _______________  _____________  ~~  ~~ ~~~2001)
Female  Population '000  3,533  140  94  102  11  1,269  463  5,612  gender split in Zimbabwe
Formal  and Zambia, and
Employed  employment in Namibia
_________  ~~~~~~~~~~~~~based  on averages:
HIV prevalence  25%  22%  39%  27%  34%  27%  25%  ANC prevalence
Partner HIV prevalence  20%  28%  20%  SA study, Botswana ASSA
simulation
5 yr Period probability  33%  33%  30%  32%  32%  32%  33%  ASSA simulation,  femnale RSK
sn______ prealnce12  14  1%  DS  group
STI  prevalence  12%  14%  12%  DHS South Africa
Partner STI  prevalence  12%  14%  12%  DHS South Africa
#  regular partners  1  1
#  regular contacts  120  120
Regular condom use  6%  11%  7%  Adetunji and others (2000,
2001), DHS South Africa
#  new contacts  3  3
new condom use  16%  11%  38%  50%  24%  Adetunji and others (2000.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  _  _ _  _  _ _  _ _  _  _  _ _  _  _  _ _  _  _ _  _  _  _  _  _  _  _ _  _  _  _  _  _  _ _  _  _  _ _  _  _ _  _  _ _  _  22  0  0  1
High Risk  Population  '000  1,824  67  49  28  22  147  86  2,223  No. of non passenger vehicles
Transport  HIV prevalence  56%  61%  56%  SA study, Botswana ASSA
Workers  simulation
Partner HIV prevalence  56%  64%  86%  69%  59%  Country studies, Botswana
ASSA  simulation
5 yr Period probability  34%  31%  34%  ASSA simulation, male STD
group
STI prevalence  30%  30%  DHS South Africa
Partner STI prevalence  17%  17%
# regular partners  1  1
# regular contacts  300  300
Regular condom use  13%  13%  DHS South Africa
#new  contacts  600  600
new condom use  47%  47%  DHS South Africa
Teachers  Population '000  136  2  7  3  3  28  10  189
HIV prevalence  26%  36%  26%  SA adult prev 30-44
Partner HIV prevalence  20%  7%  19%
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5 yr Period probability  30%  29%  30%  ASSA simulation,  female RSK
group
STI  prevalence  12%  14%  12%  DHS South Africa
Partner STI  prevalence  12%  14%  12%  DHS South Africa
# regular partners  1  1
# regular contacts  120  120
Regular condom use  6%  19%  7%  DHS South Africa
#  new contacts  86  86
new condom use  50%  29%  44%  Adetunji  and others (2000,
2001)
Cross-  Population  000  184  184
Border  HIV prevalence  42%  38%  65%  46%  58%  46%  42%  1.7  times the prevalence of
Migrants  adult men
Partner HIV prevalence  25%  22%  39%  27%  34%  27%  25%  ANC prevalence
5 yr Period probability  20%  22%  27%  19%  33%  19%  20%  ASSA simulation, male RSK
________  __________  __________  ________  ~group
STI prevalence  12%  14%  12%  DHS South Africa
Partner STI  prevalence  12%  14%  12%  DHS South Africa
# regular partners  1  1
#  regular contacts  400  400
Regular condom use  6%  19%  6%  Adetunji and others (2000,
_ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ ___  2001).  DHS South Africa
# new contacts  200  200
new condom use  40%  50%  29%  40%  Adetunji and others (2000.
__________  _____________  _____________  ~~ ~~ ~~2001)
Pregnant  Population '000  980  55  46  60  39  360  407  1,947  from fertility data
Women  HIV prevalence  25%  22%  39%  27%  34%  27%  26%  ANC prevalence
(ANC)  Partner HIV prevalence  20%  23%  _  20%  SA  average, Botswana  ASSA
Period  probability  ~~~~~~~~~~ooi  ',~~~~o,  -~~~~no,  ~simulation
5 yr Period probability  33%  34%  29%  33%  31%  33%  33%  ASSA simulation, female RSK
_____________________________  ~~~~~~~Igroup
STI  prevalence  10%  10%  DHS South Africa
Partner STI prevalence  12%  12%  DHS South Africa
# regular partners  1  1
# regular contacts  120  120
Regular condom use  6%  6%  DHS South Africa
#  new  contacts  15  _  15
new condom use  16%  16%  DHS South Africa
Newborn  Population '000  1,087  63  48  67  43  463  457  2,228  from fertility data
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Babies in  HIV prevalence  8%  9%  8%  ASSA simulation, average
Clinics  child group
Partner HIV prevalence  0%  0%  N/A
5 yr Period probability  0%  0%  0%  ASSA simulation, average
_________  _  _child  group
STI  prevalence  0%  0%  N/A
Partner STI  prevalence  0%  0%  N/A
#  regular partners  0  0  N/A
#  regular contacts  . 0  N/A
Regular condom use  0%  0%  N/A
#  new contacts  0  0  N/A
new condom  use  0%  0%  N/A
Adolescent  Population '000  1,892  48  56  28  30  402  161  2,617  from enrollment data
Boys (in  HIV prevalence  0%  0%  assumption
school)  Partner HIV prevalence  10%  10%  female assumption
5 yr Period probability  19%  19%  ASSA simulation, male RSK
__________  __________  ________  ~~~group
STI prevalence  10%  2%  9%  DHS South Africa
Partner Sn prevalence  12%  12%  DHS South Africa
# regular partners  1  1
# regular contacts  300  300
Regular condom use  19%  19%  DHS  South Africa
# new contacts  300  300
new condom  use  21%  21%  DHS  South Africa
Adolescent  Population '000  2,052  56  62  40  28  348  99  2,685  from enrollment data
Girls (in  HIV prevalence  1 %  1%  assumption
school)  Partner HIV prevalence  20%  20%  SA average
5 yr Period probability  34%  34%  ASSA simulation,  female RSK
____________  ________  __________  ~~~~ ~~~~group
STI prevalence  5%  2%  5%  DHS South Africa
Partner Sn1  prevalence  12%  12%  DHS South Africa
#  regular partners  1  1
# regular contacts  300  =  300
Regular condom use  19%  11%  18%  DHS South Africa
# new contacts  300  300
new condom use  21%  11%  21%  DH5 South Africa
37Appendix 2. Calculations of infections  averted
Primary  infections averted
The probability of a "primary" infection refers to whether or not an
individual would have been infected with HIV without having been vaccinated. It
does not include the probability that the individual would have gone on to infect
other people. This is referred to as "secondary"  infection.
The number of primary infections averted for a group of HIV negative
vaccinated  individuals will depend on four factors:
*  The efficacy of the vaccine - i.e., the probability that a vaccinated person is
protected from infection
*  The number of people in the group being vaccinated
*  The duration of the period of immunity offered by the vaccine
*  The average probability that a typical group member would otherwise have
become infected during the period of protection of the vaccine.
In general,  the number of primary cases averted by vaccinating an HIV
negative individual may be expressed as a simple product,  as follows:
PI(t)=VE*N*Pd(t)  (1)
where:  PI(t)  = primary infections averted by vaccination  at time t
VE  = efficacy of the vaccine  (between 0 and 1)
N  = size of the group
Pd(t)  = period infection probability  for the group at time t
d  = duration of protection of the vaccine
The meaning of the "period infection probability"  depends on the length of
the period. If the period under consideration  is one year, then the period
probability is equal to the probability that an individual will be infected  during
that year. This is also the definition of the incidence of HIV infection for the group.
For periods of longer than one year, the period probability must be calculated
from the incidence within the group for each of the years in the period, as follows:
d -I
Pd (t)  = I-[I  (1  - I(t + i))  (2)
i=O
where:  Pd(t)  = period probability of infection at time t
d  = duration of period
I(t)  = HIV incidence at time t (1  year probability of infection)
Equation 6.2 shows that the period probability (and therefore the primary
cases averted from equation 6.1) depends  on the way in which HIV incidence
(labeled I)  is expected to evolve for the cohort over the period.  The evolution of
38HIV incidence is in turn dependent upon the expected risk behavior of the cohort
over this period and will vary considerably between different risk groups.
Figure 1 shows the relationship between a 5-year period probability and
HIV prevalence for a high-risk group and the way in which it might evolve as the
group ages.
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The figure shows an illustrative loop, which the cohort group will traverse
in an counter-clockwise direction.  For a cohort of HIV negative 12 year olds, both
prevalence and period probability  are close to zero and will remain so until the
cohort begins sexual activity or other risk behavior. When this begins (stage 1), the
period probability will rise rapidly, while prevalence rises much more slowly,
since few individuals in the group are infected at first. After a few years,
prevalence will begin to rise more rapidly and the period probability will begin to
fall, as some individuals are already infected  and the pool of uninfected members
is smaller (stage 2). This trend will continue so that there is a negative  relationship
between prevalence and period probability (period probability falls while
prevalence rises) until significant numbers of the cohort begin to die. At this point,
at the top of the loop, prevalence begins to fall, while period probability also falls
because there is less risk behavior among older people (stage 3).
Different risk groups are typically in different parts of this cycle. For
example, commercial sex workers who have been working for a number of years
would exhibit very high prevalence but relatively low incidence  - they are near
the top of the loop (end of stage 2). Teenage girls who have just begun sexual
activity would be expected to exhibit high incidence but low prevalence - they are
at the right-hand side (end of stage 1) of the loop.
The size of the illustrated loop would depend upon the degree of risk
behavior for the group concerned.  Figure 2 shows how these relationships might
evolve for a set of illustrative  risk groups. As can be seen, the more pronounced
39the risk behavior of the group, the larger the scale of the loop, so that the group
exhibits higher incidence at the early stages and higher prevalence at the later
stages.
Figure 2.  HIV prevalence and infection  probability for different risk groups
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When individuals move from one risk group to another  (for example, when
an adolescent girl becomes a commercial sex worker, or a commercial sex worker
stops sex work), then their risk profile would move from one of these curves to
another, representing  a change from one type of risk behavior to a different one.
The analysis estimated the primary cases averted by simulating the
evolution of prevalence and infection probability for different risk groups. This
made use of the illustrative risk groups as represented in the simulation model
developed  by the Actuarial Society of South Africa (ASSA). The results are shown
in Figure 2. Although it is no substitute for the use of real data (which are lacking).
the benefit of this method is that it gives a realistic estimate of the period
probability in a Southern African setting, while arriving at a "best guess"  at the
differences  in likely risk behavior between the different risk groups.
Secondary infections averted
A variety of variables  is instrumental  in determining the number of
secondary infections averted. These include:
*  the number of sexual partners the individual will have over the period for
which the vaccine offers protection
*  the number of sexual contacts with these partners
*  their probability of being infected,  per sexual contact
*  whether they, or their partners, have a sexually transmitted infection  (STI)
40*  whether their partners are already infected with HIV
*  the frequency of condom use.
It is necessary  to calculate the probable number of people the individual
would have infected if he or she had not been successfully vaccinated.  The more
sexual partners and more sexual contacts they have, the higher the number of
people they would infect.  Similarly, the greater the individuals' probability of
having an STI and the higher the STI prevalence  of their partners,  the higher the
probability - per sexual contact - that they would transmit HIV. On the other
hand, the higher their condom use the lower the probability of transmission per
contact. Finally, the higher the existing level of HIV among their partners, the
lower the chance that their future partners are HIV negative to begin with.
Preventing a repeat infection of an already infected individual is not an infection
averted.
The number of secondary infections averted was calculated for each risk
group based on the above variables and the following formula:
Secondary infections averted  (SI)  =
Casual Partners Infections Averted (CPIA) +
Regular Partners Infections Averted  (RPIA)  (3)
Individuals are likely to have different sexual behavior with regular partners than
with casual partners. These different behaviors necessitate  the use of different
formulae to calculate secondary infections  averted, as follows:
CPIA =  [CCTd * (l-PP)]  * [(NC*RNC)  + (C*RC)]  (4)
Where:
CCTd  = The number of sexual contacts with casual partners
PP  = The probability that the partner is already HIV positive
NC  = The proportion of contacts where a condom is not used
RNC  = The risk of HIV transmission per sexual contact without a condom
C  = The proportion of contacts where a condom is used =(1-NC)
RC  = The risk of HIV transmission per sexual contact with a condom
d  = duration of efficacy of the vaccine
The equation  is broken into two sections. The first estimates the probability
that the contact was with an HIV negative partner. The second half estimates the
probability that the contact would have resulted in transmission of HIV if the
individual had not been vaccinated. The second half consists of a weighted
average of the risk of transmission with and without the use of a condom  (the
weight is determined by the level of condom use). The risk with and without a
condom is calculated as follows:
RNC = STD*STII*(IPS+PPS)  (5)
41RC = RNC*CE  (6)
Where:
STD  = The risk of transmission between otherwise healthy adults (differs
depending on the sex of the individual)
STII  = The STI inflator, the factor by which the presence of an STI in one
partner increases the risk of transmission
IPS  = The individuals probability of being infected with an STI
PPS  = The partners probability of being infected with an STI
CE  = Condom efficacy
The equation implies that the STI inflator is doubled when an STI is present
in both partners. The expression assumes that the prevalence of STIs is
independently distributed from that of HIV infection. Without this assumption,
calculations become cumbersome and time consuming and change little in the
final result.
The calculation of secondary infections among regular partners is
somewhat different. If the method outlined above for casual partners were used, it
would be possible for a situation to arise where the prevention of one infection
would be counted more than once. It is necessary, therefore,  to adjust the formula
as follows:
RPIA  = NP * (1-PP) * [NC(1-(1-RNC)A  RCTd)  + C(1-(l-RC)A  RCTd)]  (7)
Where:
NP  = The number of regular partners
RCTd  = The number of sexual contacts per regular partner
The calculation of risk with and without a condom remains the same.
The values of the variables included in these equations will be determined
by the duration of efficacy of the vaccine. The number of contacts and the number
of sexual partners will apply to the period for which the vaccine is effective. The
efficacy of the vaccine makes no difference to the calculations at this stage. These
calculations are based on the assumption that the primary infection has been
averted.
The above calculations effectively assume that had the individual not been
vaccinated,  he or she would have become infected the very next time having sex.
The combination, in the following section, of primary and secondary infection
calculations will address this problem. Secondary infections averted will only be
included for primary infections averted, averaged over the period. Although there
are more sophisticated  methods to achieve this correction,  they would complicate
the analysis and would have little effect on the magnitude of secondary infections
or the ranking of target groups in terms of effectiveness.
42It is also possible that a vaccine may lead to changes in sexual behavior
resulting from changed perceptions of risk. In the calculations  presented in this
paper, no attempt has been made to introduce behavior change. The behavior
variables used in the calculations are based on the data that are available, which
are weak and incomplete. There is therefore no quantitative  basis for estimating
the impact of a vaccine on behavior change in the different risk groups, so it
would not affect the relative ranking of the groups in terms of effectiveness.  The
implications of changes in behavior prompted by the introduction of a vaccine are,
however, discussed below.
The above approach to calculating secondary infections has a number of
limitations. First, the method assumes that sexual partners can be divided into two
groups-casual one-time partners and long-term partners. In reality, these are the
two extremes and there exists a host of different combinations.  These could be
included by estimating an equation 2.8 for all the different number of sexual
contacts. This would however greatly increase the computational burden, and
given that such desegregated  data does not exist, such an approach was not used.
This omission results in an over estimation of secondary infections averted,  as a
result of double counting for groups with a high number of infrequent but not
once off sexual partners. Effectively this means that the calculations over estimate
the effectiveness of vaccinating  high-risk groups
Second, the calculations do not consider the possibility that future partners
may also have been vaccinated. The method, therefore, over estimates the
effectiveness for all groups. However,  the focus of the paper is on where to begin a
vaccination strategy, and this issue is not of critical importance at this stage.
Evaluating a broad based vaccination  programs requires the use of complex
simulation models, which have been deemed beyond the scope of this work (see
Stover and others 2002 for an example of this work).
Third, the calculations make the simplifying assumption that STIs and HIV
among future partners are distributed independently of each other. Again, this
simplification  was made to avoid over complicating  the analysis.
Total infections averted
The previous two sections have outlined the calculation  of the number of
primary and secondary infections averted. The estimation of the total number of
infections averted per vaccinated HIV negative individuals involves the
combination of the previous two calculations as follows:
Infections averted = VE * [primary + (primary*secondary)]  (8)
Where:
VE  = the efficacy of the vaccine
primary  = the probability that the individual would have been infected
had they not received the vaccine
43secondary  = the number of infections averted by avoiding a primary
infection
Unless the possibility of behavior change as a result of vaccination is
introduced into the calculation, the efficacy  of the vaccine will still make no
difference to the ranking of strategies in terms of their effectiveness.  Given a
decision to vaccinate,  which would in part be motivated  by the efficacy,  the most
effective strategies will be the most effective regardless of the efficacy of the
vaccine. A change  in the efficacy changes the impact of vaccination  of all groups
by the same proportion and will not affect their effectiveness  in relation to one
another.  Changes in the duration of protection are, however,  more important  at
this stage. While behavior change is not included in the calculations,  it is discussed
in the text
Changes in the duration change the probability of averting a primary
infection. This change will have different implications  for the effectiveness  of
vaccinations in different risk groups.
Infections averted  per 100 entrants into the program
The method described above estimates the number of infections averted per
vaccine administered to an HIV negative individual. The vaccination of an HIV
positive individual will result in no infections averted and may well lead to a false
sense of security which could increase the risk of others. Considering only the
number of infections averted in this way ignores the costs and complications
associated  with ensuring that only HIV negative individuals receive vaccinations.
A more meaningful measure would be the number of infections averted per 100
entrants into a vaccination program. This calculation was as follows:
PerlOO = Total infections averted  * (1-target group prevalence)*100  (9)
The vaccination of members of high-risk groups is likely to avert more
infections than the vaccination of members of lower risk groups. The impact is,
however, likely to be diluted by the need to exclude many vaccination candidates
because they are already HIV positive. If the cost of screening  is significant
relative to the cost of a vaccine,  this may have important implications  for policy.
Policy decisions may be further complicated  by the difficulties associated with
locating members of high-risk groups.
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